No connection

Search Results

GKOS vs LLY

GKOS
Glaukos Corporation
NEUTRAL
Price
$122.07
Market Cap
$7.14B
Sector
Healthcare
AI Confidence
80%
LLY
Eli Lilly and Company
NEUTRAL
Price
$958.65
Market Cap
$858.01B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GKOS
--
LLY
41.7
Forward P/E
GKOS
282.75
LLY
22.78
P/B Ratio
GKOS
10.7
LLY
32.33
P/S Ratio
GKOS
14.08
LLY
13.16
EV/EBITDA
GKOS
-142.15
LLY
27.08

Profitability

Gross Margin
GKOS
77.96%
LLY
83.04%
Operating Margin
GKOS
-18.87%
LLY
44.9%
Profit Margin
GKOS
-36.99%
LLY
31.67%
ROE
GKOS
-26.38%
LLY
101.16%
ROA
GKOS
-5.8%
LLY
19.41%

Growth

Revenue Growth
GKOS
35.7%
LLY
42.6%
Earnings Growth
GKOS
--
LLY
51.4%

Financial Health

Debt/Equity
GKOS
0.16
LLY
1.65
Current Ratio
GKOS
4.69
LLY
1.58
Quick Ratio
GKOS
3.83
LLY
0.78

Dividends

Dividend Yield
GKOS
--
LLY
0.68%
Payout Ratio
GKOS
0.0%
LLY
26.14%

AI Verdict

GKOS NEUTRAL

GKOS presents a dichotomy between strong operational growth and extreme valuation. The Piotroski F-Score of 5/9 indicates a stable financial foundation, supported by an exceptional current ratio of 4.69 and very low debt/equity (0.16). However, the company remains unprofitable with a negative profit margin of -36.99% and a staggering forward P/E of 282.75. While revenue growth is robust at 35.7%, the bearish insider sentiment and weak technical trend suggest a disconnect between analyst optimism and internal confidence.

Strengths
Strong revenue growth (35.7% YoY)
Excellent liquidity with a current ratio of 4.69
High gross margins (77.96%) indicating strong product pricing power
Risks
Extreme valuation metrics (Forward P/E 282.75, P/S 14.08)
Persistent lack of profitability over 25 consecutive quarters
Bearish insider activity with $6.41M in sales and zero buys
LLY NEUTRAL

LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)

Compare Another Pair

GKOS vs LLY: Head-to-Head Comparison

This page compares Glaukos Corporation (GKOS) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile